Patients with an advanced form of skin cancer were given new hope today after the health watchdog recommended that two life-extending treatments should be available on the NHS.
Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E–mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–mutant cells but activates ERK signaling in BRAF wild-type cells. This paradoxical activation of ERK signaling is the mechanistic basis for the development of RAS-mutant squamous-cell skin cancers in patients treated with RAF inhibitors. This study reports the accelerated growth of a previously unsuspected RAS-mutant leukemia in a patient with melanoma who was receiving vemurafenib. Exposure to vemurafenib induced hyperactivation of ERK signaling and proliferation of the leukemic cell population, an effect that was reversed on drug withdrawal.
Phase I melanoma patient trial will test whether the drug PV-10 works better in patients with a distinct immune biomarker signature in both blood and tumor tissue.
Circulating tumor cells detected in the blood of stage III melanoma patients may be a predictive blood biomarker helpful for deciding which patients could benefit from aggressive adjuvant therapy.
In an industry-academia collaboration, researchers have found an intermittent dose of vemurafenib, an oral BRAF inhibitor used to treat metastatic melanoma can help delay resistance in a mouse model. The results have implications for patients taking the drug.
Researchers at Washington University found mutations in the gene SF3B1 are associated with a type of uveal melanoma that has better outcomes and is less likely to spread to other parts of the body.
Researchers assessed latest apps that claim to help diagnose questionable moles as melanoma. The performance of the apps is highlight variable- 3 of 4 apps incorrectly classified one-third of melanomas as “not concerning”.
Still in the pre-clinical stages, IL-17E immunotherapy is slated to enter clincial tirals as monotherapy and combo therapy for cancers including melanoma, pancreatic, gastric, colon, ovarian, breast, and lung cancers.
Researchers at the Dana-Farber and Broad Institute in Boston identified 2 mutations that collectively occur in 71 percent of malignant melanoma tumors making them more common than the BRAF mutation. These highly “recurrent” mutations may be the most common mutations in melanoma cells found to date. The mutations are located in non-protein-coding DNA that regulates the activity of genes, both located in the promoter region of TERT, the telomerase enzyme